126 results about "Bile fluid" patented technology

The invention relates to the field of bile monitoring and analysis, in particular to a dynamic bile monitoring and analysis method and device based on real-time image recognition. The method comprises the following steps: continuously collecting a bile monitoring image sequence of a drainage bag of a patient, and carrying out global image resolution optimization and multi-frame color drift analysis to obtain a multi-time-point bile color evolution sequence; performing comprehensive bile physical state vector modeling according to the bile monitoring image sequence, performing personalized bile state characteristic evolution, and constructing a bile color-property comprehensive characteristic spectrum; and performing deep color component visual detection based on the multi-time-point bile color evolution sequence, performing pathological concentration change mining, and constructing a concentration anomaly evolution model. According to the method, the real-time bile state characteristics of the patient are accurately analyzed based on precision visual identification, the risk level and deterioration prediction are combined, the dynamic adjustment of the precise early warning time point is realized, and the response speed and the early warning accuracy are improved.

The invention relates to the technical field of intelligent medical care, and discloses a drainage port nursing recommendation method and system for a patient with bile leakage. The system comprises a data acquisition module used for acquiring bile drainage data and state data of skin around a drainage port in real time; the cloud decision module is internally provided with a nursing scheme recommendation model associated with a bile leakage nursing knowledge graph, and is used for carrying out fusion analysis on the multi-modal data and generating a personalized nursing plan; the local execution terminal is used for receiving and displaying the nursing plan and guiding nursing personnel to execute and record actual nursing operation data; and the closed-loop feedback module is used for returning the actual execution data and the post-nursing state data so as to optimize the nursing scheme recommendation model and the bile leakage nursing knowledge graph. The technical problems that in traditional nursing, evaluation is subjective, decision-making depends on experience, execution is not standard, and knowledge is difficult to accumulate are solved, and standardization, individuation and continuous self-optimization of bile leakage drainage opening nursing are achieved.

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

The invention provides a strain of high-temperature-resistant and inflammation-relieving Witzia ciliaris and an application thereof, the high-temperature-resistant and inflammation-relieving Witzia ciliaris is Witzia ciliaris CN985 and is preserved in the China Center for Type Culture Collection (CCTCC), the preservation date is April 7, 2024, and the preservation number is CCTCC NO: M 2024641. The invention further provides a preparation method of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain for preventing and treating inflammation of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain for preventing and treating inflammation of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain. The invention provides a brand new strain of Witzia ciliaris CN985, which is resistant to high temperature, has better acid resistance and bile resistance, and has no hemolysis risk when being applied to a human body. The Witzia coagulans CN985 has excellent antibacterial performance, and especially can significantly inhibit streptococcus pyogenes, salmonella enteritidis and / or group B streptococcus; besides, experimental results show that the Witzia ciliaris CN985 can relieve enteritis, improve the immunity of the organism and relieve pharyngitis, and especially when the Witzia ciliaris CN985 and the phytobacterium plantarum CE18 are combined for use, the Witzia ciliaris CN985 and the phytobacterium plantarum CE18 have a synergistic interaction effect, so that the relieving effect on enteritis can be remarkably improved.

The invention relates to the technical field of bioengineering, in particular to a preparation method of a probiotic and exosome preparation applied to immunoregulation. The probiotics and the umbilical cord stem cell exosome are combined for use, the immune regulation effect is enhanced from multiple targets and multiple ways, the immune function of the body is improved, the exosome carries a specific molecular marker and acts on immune cells in a targeted mode, precise immune regulation is achieved, and the preparation is in an oral form and convenient to use; the exosome is extracted from umbilical cord stem cells, has no pathogenicity and immunogenicity, and is low in adverse reaction risk after being used for a long time, and the prepared combined preparation can be used for treating and preventing various immune-related diseases, and also can be used for daily conditioning of people with low immunity and improving the body resistance; meanwhile, the combined preparation adopts micro-capsule embedding, so that the probiotics can be effectively protected from gastric acid and bile erosion, the survival rate and colonization efficiency of the probiotics in intestinal tracts are improved, the immunoregulation effect is further enhanced, and the combined preparation is convenient to store and transport and has a good application prospect.

The invention discloses a postoperative recurrence monitoring system and method for bile liquid biopsy, and relates to the technical field of medical detection, and the method comprises the following steps: obtaining medication data, bile liquid data and gene data of a target object; preprocessing the medication data and the bile liquid data to generate a sampling interference index sequence, and further performing weighted fusion on the gene data by the sampling interference index sequence to obtain a mutation load index of each gene detection time point; and within the time sequence range of the gene data, performing sliding window analysis on the sampling interference index sequence to generate an abnormal chain marker sequence. According to the method, the time sequence mismatch degree is accurately quantified by constructing a time difference matrix, and a weight distribution mechanism is dynamically adjusted in combination with medication volatility, so that the generation process of the sampling interference index can adaptively reflect the influence of medication mode change on the sampling quality; the problem of interference evaluation deviation caused by mismatching of medication data and bile sampling time is effectively solved.

This article provides methods for treating progressive familial intrahepatic cholestasis of blood (PFIC), including, for example, PFIC2 (bial salt export pump (BSEP) deficiency), using ileal bile acid transport (IBAT) inhibitors (such as ozexibart or a pharmaceutically acceptable salt thereof). These methods may include identifying or selecting subjects with a higher percentage of unconjugated serum bile acids relative to a reference level and administering an IBAT inhibitor to the identified or selected subject.

The invention discloses application of a compound AZD5718 in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and belongs to the field of biological medicines. The compound AZD5718 can effectively improve hepatocyte damage and bile metabolism disorder caused by Mdr2 gene deletion, provides solid experimental data support for developing novel drugs for treating cholestatic liver diseases, is expected to provide differentiated therapeutic drug choices for clinic, and has important medical value and social significance.

The subject matter disclosed describes a method of treating pruritus in a subject with cholestatic liver disease in need thereof, comprising administering a therapeutically effective amount of nalmefene to the subject, wherein the subject achieves an improvement in pruritus within 24 hours following administration of nalmefene.

Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.

The invention discloses a preparation method of tacrolimus capsules, and relates to the technical field of medicines. The preparation method comprises the following steps: S1, preparing a drug-loaded pellet core; s2, coating and curing a flexible buffer layer, namely curing for 8 hours under the conditions that the temperature is 100 DEG C and the relative humidity is 35%, so that the xanthan gum is in a swelling state; s3, coating with a high-barrier layer; s4, protective controlled release layer coating: preparing a coating solution from the third polymer grafted with the lipophilic bile salt derivative and phospholipid; and S5, capsule filling. Through functional gradient multilayer structure design and fine regulation and control of phospholipid composition and spatial distribution, multiple technical problems of poor chemical stability of tacrolimus, brittle rupture of a coating, burst drug release, dissolution and absorption disorder and release drift caused by individual difference of gastric emptying are synergistically solved; the excellent mechanical strength, stable and controllable release kinetics and obvious solubilization promoting effect of the pellet are realized. The method is clear in technological parameters and suitable for industrial production.

The invention belongs to the field of microorganisms and medicine health care, and relates to an ackermania muciniphila strain and application thereof, the preservation number of the ackermania muciniphila strain is CGMCC (China General Microbiological Culture Collection Center) No.34370, and a 16SrDNA (Deoxyribose Nucleic Acid) sequence of the ackermania muciniphila strain has 93% similarity with a sequence shown as SEQ ID NO: 1. The new ackermania muciniphila strain (AKKBC300) is separated from a healthy human body and has good safety; good tolerance to low pH value and bile salt is shown in vitro, and it is indicated that the compound can reach the intestinal tract through the upper digestive tract and play a role; according to the present invention, genomics analysis results prove that the bacterial strain contains the gene Akkermansia BC00573 with high homology with the known probiotic functional protein Amuc1100, such that the molecular basis is provided;

The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1, 5-a]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

The invention discloses a probiotic which is derived from human milk and has the effects of resisting oxidation, resisting inflammation, protecting tissues and protecting intestinal barriers and application of the probiotic. Lactobacillus paracasei DPUMW-M14-9 is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms, and the preservation number is CCTCC M 20252990. The strain has the characteristics of acid resistance, bile resistance, strong oxidation resistance, high surface hydrophobicity, self-aggregation capability and the like. The lactobacillus paracasei DPUMW-M14-9 can effectively adhere to epithelial cells, promote cell proliferation and regulate and control the process of a cell cycle. The bacterial strain can be used for inhibiting proinflammatory cytokines (TNF-alpha, IL-6 and IL-1beta) induced by lipopolysaccharide (LPS) and repairing tight junction proteins (ZO-1, Occludin and Claudin-1) at the same time, so that the integrity of epithelial cells is enhanced.

The application discloses an automatic pressure regulating negative pressure suction device with automatic humidification function, which comprises a tracheal catheter, a closed sputum suction tube connected to the tail end of the tracheal catheter, a humidification tube connected to a humidification tube port on the closed sputum suction tube, an infusion device connected to the upper end of the humidification tube, sterile humidification liquid connected to the infusion device, a quantitative injection device additionally arranged outside a Murphy dropper of the infusion device, and a pressure pump provided with a volume sensor and a closed air bag wrapping the Murphy dropper, wherein the tail end of the closed sputum suction tube is connected to a disposable negative pressure suction liquid storage bottle through a suction device leather strap, and another connecting port of the negative pressure suction bottle is connected to a negative pressure suction pressure regulating table. According to the application, pressure modules are selected according to different suction liquids (sputum, bile, intestinal fluid, cerebrospinal fluid, etc.), a standard negative pressure value range is adjusted by one key, and the application is convenient to use. In addition, the automatic humidification can be performed on thick sputum for the sputum suction operation, the sputum is made to be thin, and the suction is facilitated.

The invention provides a construction method of an HBV (Hepatitis B Virus) infection model based on multilineage hepatobiliary organs, which comprises the following steps: differentiating human pluripotent stem cells to form immune cell-containing hepatobiliary organs for further maturation culture, and enabling the hepatobiliary organs to be mature in function and highly express NTCP (Natriuretic Therapeutic Cells) by using a maturation culture medium containing bile metabolism substrate cholesterol and deoxybear bile acid, so as to obtain the HBV infection model based on the multilineage hepatobiliary organs. And then infecting the mature organs by adopting an HBV virus strain generated by HepAD38 cells to construct an in-vitro model which is susceptible to HBV and can maintain an infection state for a long time. According to the construction method, the liver infection and immune interaction microenvironment can be simulated more truly, and a stable and reliable experimental platform is provided for HBV infection mechanism research and anti-HBV drug screening.

The invention belongs to the technical field of biochemical pharmacy, and particularly relates to a compound bezoar composition, decoction piece type compound bezoar and a preparation method of the decoction piece type compound bezoar. The compound calculus bovis composition provided by the invention comprises 94-96% by mass of main agents and 8 kinds of calculus bovis intermediates, the mass content of the auxiliary agent is 4-6%, and the auxiliary agent is six commercially available finished product combined cholic acid. The bilirubin content of the bezoar intermediate used in the invention is increased by more than 30% and the yield is increased by more than 25% compared with the existing biochemical reaction process of oxgall. The DPPH free radical scavenging rate of the compound bezoar composition reaches 89.6% + / -2.1% and is increased by 25.7-36.9% compared with 58.3% + / -3.5% of a product prepared from ox bile, and through t inspection, p is smaller than 0.01 (n is equal to 5). Free cholic acid intervention is strictly prohibited, lithocholic acid addition is completely eradicated, and the composition has the advantages of being high in bilirubin content, high in oxidation resistance and high in biological activity and adapts to the physiological characteristics of the human body.

The invention belongs to the technical field of microorganisms, and relates to a lactobacillus paracasei Lpc-14 strain with functions of resisting oxidation and promoting gastrointestinal motility and a preparation method of the lactobacillus paracasei Lpc-14, the lactobacillus paracasei is classified and named as Lactobacillus paracasei, the preservation number of the lactobacillus paracasei is CGMCC No. 29666, the preservation time is January 18, 2024, and the preservation number of the lactobacillus paracasei Lpc-14 is CGMCC No. 29666. The preservation unit is China General Microbiological Culture Collection Center, and the address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain is separated and purified from naturally-fermented Chinese sauerkraut fermentation liquor, has the capacity of resisting oxidation and promoting gastrointestinal motility of mice with constipation and improving secretion of gastrointestinal regulating peptides, further has the capacity of resisting acid and alkali and resisting artificial simulated gastrointestinal fluid and bile, and has the characteristics of probiotics.

This invention discloses a postoperative bile fistula risk prediction system for hepatobiliary surgery patients, belonging to the field of bile fistula risk data processing technology. The system includes an evidence-driven variable acquisition module, a standardization judgment module, a time-series feature generation module, a feature screening module, and a dynamic prediction module. It performs time-series reconstruction and evolutionary feature extraction for dynamic monitoring indicators of postoperative bile extravasation. Through a structural-biochemical consistency constraint screening method, it fuses and filters features of structural risk channels, biochemical risk channels, and time-series evolution channels. Based on core predictive feature data, it constructs a bile fistula risk prediction model and dynamically predicts the probability of bile fistula occurrence at different postoperative time points through a time-series rolling update mechanism, outputting risk levels and early warning results. This invention enables early identification, dynamic assessment, and individualized intervention support for bile fistula risk, improving the accuracy of prediction results and its clinical application value.

The application provides a kind of double (2,3-dihydroxy benzamide) compound and its preparation method and application, belong to medical technology field.The application obtains a series of double (2,3-dihydroxy benzamide) compound with novel structure and good inhibiting effect on cholestatic liver disease and liver fibrosis by structural modification of sporangium chelae, the compound can significantly inhibit the expression of hepatic stellate cell COL1A1 mRNA in vitro, has strong anti-liver fibrosis effect;In vivo, it can significantly alleviate the liver injury related biochemical indicators of 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine (DDC) induced cholestatic liver disease mouse model, inhibit the expression of liver fibrosis related genes, reduce the content of liver collagen fiber, inhibit liver inflammation and bile duct response, and can be used for treating cholestatic liver disease and liver fibrosis.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation and / or fibrosis in the liver, e.g., metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), primary biliary cholangitis, primary sclerosing cholangitis, alcoholic cirrhosis, hepatitis cirrhosis, cholestasis, autoimmune hepatitis, viral hepatitis B, viral hepatitis C, hemochromatosis, Wilson's disease, or alcoholic steatohepatitis, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

The present invention relates to a pharmaceutical composition comprising elafibranor or a pharmaceutically acceptable salt thereof for use in treating primary biliary cholangitis (PBC) in subjects intolerant to ursodeoxycholic acid (UDCA).

This application relates to a bile filtration and collection device with heat preservation for bile reinfusion, belonging to the field of medical device technology. The bile filtration and collection device with heat preservation for bile reinfusion of this application includes a stirring assembly, a heating assembly, a filtering assembly, and a nutrient assembly. The stirring assembly includes a stirring drum and a stirrer, with the stirrer configured to rotate within the inner cavity of the stirring drum. The heating assembly includes a heating base disposed below the stirring drum for heating the bile within the drum. The upper end of the filtering assembly communicates with a bile drainage bag, and the lower end communicates with the inner cavity of the stirring drum for filtering the bile. The nutrient assembly is disposed around the periphery of the stirring drum for delivering nutrients into the drum. The bile filtration and collection device with heat preservation for bile reinfusion provided by this application utilizes the filtering assembly, nutrient assembly, stirring assembly, and heating assembly to perform bile filtration, nutrient supplementation, stirring, and heating, improving the convenience and comfort of bile reinfusion and enhancing the patient's treatment efficacy and comfort.

The application discloses application of AML-12 exosomes in preparation of medicines for treating cholestatic liver injury, relates to the technical field of biological medicine, and discloses application of AML-12 cell-derived exosomes in preparation of medicines for preventing and treating ANIT-induced cholestatic liver injury; the treatment is manifested as reduction of alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase levels in serum. The application proves that the AML-12 cell-derived exosomes have a significant treatment effect on ANIT-induced cholestatic liver injury, successfully opens up the application of the biological preparation in a brand-new disease field, and fills the blank of the prior art; through in-vivo experiments, it is proved that AML-12 exosome treatment can significantly reduce liver cell injury markers and alkaline phosphatase, a key index of cholestasis, in serum of ANIT model mice, and improve pathological injury of liver tissue, thereby constituting a complete curative effect evidence chain from function to morphology.

Compositions and methods of treating or preventing a reproductive disease or condition in a mammalian subject comprising administering to a mammalian subject in need thereof an effective amount of a substantially homogeneous and transformed population of enteric bacterial cells, wherein the administered bacterial cells have been engineered to express bile salt hydrolase (BSH). Compositions and methods for treating or preventing polycystic ovary syndrome (PCOS).

The invention discloses an application of 5-methoxyl serotonin in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and systematically proves that the 5-methoxyl serotonin (5MOS) has the effects of relieving hepatic fibrosis, improving accumulation of bile acid in the liver and reversing metabolism and transport of the bile acid for the first time, so that the cholestatic liver diseases can be prevented and / or treated by the 5-methoxyl serotonin (5MOS). DDC-induced cholestatic liver injury is relieved in a dose-dependent manner, and a new medication strategy is provided for treating cholestatic liver diseases.

The utility model relates to the field of medical instruments, and discloses a pancreatic duct stent. The pancreatic duct stent comprises a first end, the first end is a pancreatic duct end, and the first end is provided with an end hole and a side hole; the second end is a small intestine end, and a side hole is formed in the second end; the two ends of the middle section are connected with the first end and the second end respectively, and the middle section is provided with no side hole. The pancreatic duct support has the anti-slipping, anti-blocking and anti-injury functions, and pancreatic related operative complications are effectively reduced; moreover, the middle side-hole-free section is lengthened, the length of the middle side-hole-free section is increased to 5 cm, the middle side-hole-free section can cross a biliary-intestinal anastomotic stoma, activation of pancreatin by bile near a pancreatic-intestinal anastomotic stoma is reduced, and the pancreatic leakage occurrence rate is reduced.

This invention provides an in vitro cultured bezoar, its preparation method, and its application, belonging to the field of traditional Chinese medicine preparation technology. The preparation method of this invention involves obtaining a bile-resistant, high-β-glucuronidase-active *Escherichia coli* strain through bile gradient acclimation, which is then combined with *Enterococcus faecalis* to form a functional bacterial community. This community is then cultured in vitro through a three-stage process of proliferation, transformation, and crystallization, followed by gradient calcium ion-induced crystallization and vacuum freeze-drying to obtain in vitro cultured bezoar. This invention aims to solve the problems of low conversion efficiency, uneven crystallization, insufficient content of effective components, and unstable product quality in existing technologies. The obtained in vitro cultured bezoar product has significantly higher bilirubin and conjugated bile acid contents than the standards of the *Chinese Pharmacopoeia*, and the process is stable, controllable, and suitable for industrialization.

The invention discloses an application of an RNAm6A modification level of PTGER4 in preparation of an ICP (inductively coupled plasma) auxiliary diagnosis kit. The RNA m6A modification level of the PTGER4 in placenta tissue and whole blood of an ICP patient is remarkably reduced, and the AUC modified by the RNA m6A of the PTGER4 in the whole blood is 0.844, so that the RNA m6A modification of the PTGER4 is a biomarker highly related to ICP attack, and a laboratory support can be provided for screening, diagnosis and treatment of ICP.